Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer

Angiogenesis has been implicated in ovarian cancer pathogenesis. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been incorporated in ovarian cancer treatment in combination with chemotherapy both in a frontline setting and in disease recurrence. However, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Liontos, Michalis, Lykka, Maria, Dimopoulos, Meletios-Athanasios, Bamias, Aristotle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199819/
https://www.ncbi.nlm.nih.gov/pubmed/25336975
http://dx.doi.org/10.2147/OTT.S65522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199819/
https://www.ncbi.nlm.nih.gov/pubmed/25336975
http://dx.doi.org/10.2147/OTT.S65522

Ejemplares similares